ATE117434T1 - Gefriergetrocknete zusammensetzung, die ein mit meerrettichperoxydase markiertes fab'-fragment eines gegen menschliches beta-interferon gerichteten antikörpers und trehalose enthält; eia kit, der diese zusammensetzung enthält. - Google Patents

Gefriergetrocknete zusammensetzung, die ein mit meerrettichperoxydase markiertes fab'-fragment eines gegen menschliches beta-interferon gerichteten antikörpers und trehalose enthält; eia kit, der diese zusammensetzung enthält.

Info

Publication number
ATE117434T1
ATE117434T1 AT89904216T AT89904216T ATE117434T1 AT E117434 T1 ATE117434 T1 AT E117434T1 AT 89904216 T AT89904216 T AT 89904216T AT 89904216 T AT89904216 T AT 89904216T AT E117434 T1 ATE117434 T1 AT E117434T1
Authority
AT
Austria
Prior art keywords
freeze
trehalose
composition
horserad
fragment
Prior art date
Application number
AT89904216T
Other languages
English (en)
Inventor
Etsuko Matsuo
Shojiro Yamazaki
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of ATE117434T1 publication Critical patent/ATE117434T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/963—Methods of stopping an enzyme reaction or stabilizing the test materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/826—Additives, e.g. buffers, diluents, preservatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT89904216T 1988-03-30 1989-03-29 Gefriergetrocknete zusammensetzung, die ein mit meerrettichperoxydase markiertes fab'-fragment eines gegen menschliches beta-interferon gerichteten antikörpers und trehalose enthält; eia kit, der diese zusammensetzung enthält. ATE117434T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7688188 1988-03-30

Publications (1)

Publication Number Publication Date
ATE117434T1 true ATE117434T1 (de) 1995-02-15

Family

ID=13617977

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89904216T ATE117434T1 (de) 1988-03-30 1989-03-29 Gefriergetrocknete zusammensetzung, die ein mit meerrettichperoxydase markiertes fab'-fragment eines gegen menschliches beta-interferon gerichteten antikörpers und trehalose enthält; eia kit, der diese zusammensetzung enthält.

Country Status (5)

Country Link
US (1) US5262296A (de)
EP (1) EP0365685B1 (de)
AT (1) ATE117434T1 (de)
DE (1) DE68920693T2 (de)
WO (1) WO1989009402A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102788A (en) * 1988-11-21 1992-04-07 Hygeia Sciences, Inc. Immunoassay including lyophilized reactant mixture
ES2194911T3 (es) * 1994-06-02 2003-12-01 Elan Drug Delivery Ltd Metodo para evitar la agregacion de proteinas/peptidos cuando tiene lugar su rehidratacion o descongelacion.
DE19503685C2 (de) * 1995-01-30 2000-05-31 Invitek Gmbh Verfahren zur Herstellung komplexer multienzymatischer lagerstabiler Reaktionsgemische und deren Verwendung
US5556771A (en) * 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JPH11510170A (ja) * 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP3624543B2 (ja) * 1996-05-02 2005-03-02 東ソー株式会社 免疫反応試薬及びその製造方法
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
DE59611424D1 (de) * 1996-07-16 2007-05-03 Qiagen North American Holdings Verfahren zur herstellung komplexer multienzymatischer lagerstabiler reaktionsgemische und deren verwendung
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU6008800A (en) * 1999-07-14 2001-01-30 Spectral Diagnostics Inc. Preparation of spheres for diagnostic tests
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU1344102A (en) * 2000-10-12 2002-04-22 Genentech Inc Reduced-viscosity concentrated protein formulations
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
EP3178492A1 (de) 2003-04-04 2017-06-14 Genentech, Inc. Hochkonzentrierte antikörper- und proteinformulierungen
US7038295B2 (en) * 2003-07-18 2006-05-02 Semiconductor Components Industries, L.L.C. DC/DC converter with depletion mode compound semiconductor field effect transistor switching device
RS55723B1 (sr) 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
US7426780B2 (en) 2004-11-10 2008-09-23 Enpirion, Inc. Method of manufacturing a power module
US7462317B2 (en) 2004-11-10 2008-12-09 Enpirion, Inc. Method of manufacturing an encapsulated package for a magnetic device
US7688172B2 (en) 2005-10-05 2010-03-30 Enpirion, Inc. Magnetic device having a conductive clip
US8631560B2 (en) 2005-10-05 2014-01-21 Enpirion, Inc. Method of forming a magnetic device having a conductive clip
US8139362B2 (en) 2005-10-05 2012-03-20 Enpirion, Inc. Power module with a magnetic device having a conductive clip
US8701272B2 (en) 2005-10-05 2014-04-22 Enpirion, Inc. Method of forming a power module with a magnetic device having a conductive clip
US7920042B2 (en) 2007-09-10 2011-04-05 Enpirion, Inc. Micromagnetic device and method of forming the same
US7955868B2 (en) 2007-09-10 2011-06-07 Enpirion, Inc. Method of forming a micromagnetic device
US8133529B2 (en) 2007-09-10 2012-03-13 Enpirion, Inc. Method of forming a micromagnetic device
US8018315B2 (en) * 2007-09-10 2011-09-13 Enpirion, Inc. Power converter employing a micromagnetic device
US8692532B2 (en) 2008-04-16 2014-04-08 Enpirion, Inc. Power converter with controller operable in selected modes of operation
US8686698B2 (en) * 2008-04-16 2014-04-01 Enpirion, Inc. Power converter with controller operable in selected modes of operation
US8541991B2 (en) 2008-04-16 2013-09-24 Enpirion, Inc. Power converter with controller operable in selected modes of operation
US9246390B2 (en) * 2008-04-16 2016-01-26 Enpirion, Inc. Power converter with controller operable in selected modes of operation
US8153473B2 (en) 2008-10-02 2012-04-10 Empirion, Inc. Module having a stacked passive element and method of forming the same
US9054086B2 (en) 2008-10-02 2015-06-09 Enpirion, Inc. Module having a stacked passive element and method of forming the same
US8266793B2 (en) 2008-10-02 2012-09-18 Enpirion, Inc. Module having a stacked magnetic device and semiconductor device and method of forming the same
US8339802B2 (en) 2008-10-02 2012-12-25 Enpirion, Inc. Module having a stacked magnetic device and semiconductor device and method of forming the same
US9548714B2 (en) 2008-12-29 2017-01-17 Altera Corporation Power converter with a dynamically configurable controller and output filter
US8698463B2 (en) 2008-12-29 2014-04-15 Enpirion, Inc. Power converter with a dynamically configurable controller based on a power conversion mode
KR20110128333A (ko) * 2009-03-06 2011-11-29 제넨테크, 인크. 항체 제제
US8867295B2 (en) 2010-12-17 2014-10-21 Enpirion, Inc. Power converter for a memory module
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US9509217B2 (en) 2015-04-20 2016-11-29 Altera Corporation Asymmetric power flow controller for a power converter and method of operating the same
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US10888364B2 (en) 2018-01-02 2021-01-12 Medtronic Holding Company Sarl Scoop cannula with deflectable wings
US20210223262A1 (en) * 2018-06-07 2021-07-22 Merck Sharp & Dohme Corp. Lyosphere critical reagent kit
MX2022015287A (es) * 2020-06-01 2023-02-22 Loop Diagnostics S L Metodo y kit para la deteccion temprana de septicemia.
CN116068163B (zh) * 2023-02-17 2024-06-25 中国科学院长春应用化学研究所 一种干扰素α2b的检测方法及检测试剂盒
CN117571983B (zh) * 2023-11-30 2024-08-09 苏州派博思生物技术有限公司 碱性磷酸酶快速标记试剂盒及方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0111216A3 (de) * 1980-03-31 1985-01-16 Takeda Chemical Industries, Ltd. Enzymimmunologisches Testverfahren, Peptid-Enzym-Konjugat, dessen Lyophilisat, Antikörper und Reagenzsatz dafür
US4514507A (en) * 1980-11-07 1985-04-30 Secher David S Assay for interferon
JPH0659231B2 (ja) * 1983-02-08 1994-08-10 ヤマサ醤油株式会社 単一クローン抗体
JPS6035263A (ja) * 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
JPH0677019B2 (ja) * 1984-01-17 1994-09-28 株式会社ヤトロン 酵素標識抗体の安定化法
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
DE229810T1 (de) * 1985-07-09 1987-11-05 Quadrant Bioresources Ltd., Soulbury, Leighton Buzzard, Bedfordshire Beschuetzung von proteinen und aehnlichem.
JPS62206447A (ja) * 1986-03-07 1987-09-10 Toray Ind Inc ヒトインタ−フエロン−βの微量定量法
US4880751A (en) * 1986-10-31 1989-11-14 Board Of Regents, The University Of Texas System Immunoglobulin adsorption

Also Published As

Publication number Publication date
EP0365685A1 (de) 1990-05-02
EP0365685A4 (en) 1990-09-26
DE68920693D1 (de) 1995-03-02
WO1989009402A1 (en) 1989-10-05
DE68920693T2 (de) 1995-05-24
EP0365685B1 (de) 1995-01-18
US5262296A (en) 1993-11-16

Similar Documents

Publication Publication Date Title
ATE117434T1 (de) Gefriergetrocknete zusammensetzung, die ein mit meerrettichperoxydase markiertes fab'-fragment eines gegen menschliches beta-interferon gerichteten antikörpers und trehalose enthält; eia kit, der diese zusammensetzung enthält.
PT92596A (pt) Metodo para o tratamento de choque endotoxico num mamifero, utilizando antagonistas do factor activador de plaquetas em combinacao com anticorpos monoclonais ou policlonais
ES2102007T3 (es) Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras.
DK0853661T3 (da) Specifikke bindingselementer for human transformerende vækstfaktor beta; materialer og metoder dertil
ES2145735T3 (es) Anticuerpos monoclonales contra el factor de necrosis de tumores alfa humano.
ATE71411T1 (de) Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
DK0395853T3 (da) Rekombinant proteinreceptor
DK0537166T3 (da) Vandopløselige polypeptider med stor affinitet for alfa og beta-interferon
ATE397659T1 (de) Polyklonale antikörper gegen den menschlichen alpha-pdgf-rezeptor und dessen verwendung
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
HK6196A (en) Immunochemical assay for human granulocyte-macrophage colony stimulating factor
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
FI92716C (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
RU2004106775A (ru) Антитело против интерферон-альфа/бета-связывающего белка i (ifnab-bpi)
DE59006159D1 (de) Verwendung von macrolactonen als antiallergica.
FI86255B (fi) Monoklonal antiurokinase-antikropp, den innehaollande matris och biokemiska testpackningar, i vilka den anvaendes.
ATE151812T1 (de) Neue variante von menschlichem gewebeplasminogenaktivator
DK134487D0 (da) Monoklonalt antistof med affinitet for humant interleukin-2
ATE102038T1 (de) Eliminierung von aktivierten lymphozyten.
IT1204775B (it) Kit per la determinazione dell'attivita' proliferativa nei tumori umani
IT8622820A0 (it) Composizione polipeptidica utile per la preparazione di vaccini antimalaria e di kits diagnostici per la determinazione di anticorpi antimerozoite.
FI902700A0 (fi) Vaevnadplasminogenaktivatorderivat.
TW221711B (en) N-AFP monoclonal antibody and method of preparation thereof
IT208536Z2 (it) Struttura di cannula vaginale monouso, per l'applicazione di pomate, medicamenti semidensi e simili.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties